

BioLight Will Work to Register a Level 1 ADR in the US

Suzana Nahum-Zilberberg, BioLight CEO

“We have decided to initiate registration of a ADR Level 1 in the US, which will support BioLight in presenting its unique model of management, and the leading technologies it is developing and commercializing, to a wide range of American and international investors.”

Tel Aviv, Israel, August 28, 2013 - BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT), which implements a unique strategy for encouraging innovation in the field of life sciences, through the creation of clusters of companies around a defined medical condition, announced today that the Company's Board of Directors has approved the registration of ADR Level 1, which will be traded in the over-the-counter market, subject to completion of the required procedures.

BioLight intends to take proactive steps to raise awareness of the Company and its activity, both clinical and commercial, in the US capital market. The Company estimates that implementing ADR in the US, along with continued implementation of its work plan, will lead to better awareness and interest in the Company and its technologies among strategic investors, specialized investment funds, and the American capital market in general. BioLight explains that the ADR program does not include the raising of capital in the initial phase, and the main objective is as stated above.

As the process advances, the Company will report on the structure of the ADR, and on schedules, and will provide any necessary further details.

Suzana Nahum-Zilberberg, BioLight CEO: “We have decided to advance registration of a ADR Level 1 in the US, which will enable BioLight to present its unique model of management, and the leading technologies it is developing, to a wide range of American and international investors.”

BioLight, along with its rich portfolio of companies, products and technologies, creates interest among foreign, strategic, and financial investors and implementation of such financial instrument in the US will serve as an excellent tool for presenting the group to these potential stakeholders. BioLight has two active clusters in the fields of eye treatments and cancer diagnostics, which include companies in different levels of development, from the research phase through the initial sales phase. The US market is a central large market which represents a target market for most of the Company's products. The Company's future activities in this market, as well as the value that will be created for investors from such activity, currently represent a real opportunity that BioLight presents to the market."